CG Oncology Receives FDA Fast Track: Progress on BLA Approval by 2026

The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Breakthrough Therapy designations to cretostimogene grenadenorepvec, a clinical-stage bladder cancer candidate, and CG Oncology is now submitting its Biologics License Application (BLA) on a rolling basis. The company began its BLA filing in the fourth quarter of 2025, leveraging complete response and durability data from the Phase 3 BOND-003 trial in high-risk, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). CG Oncology plans to finalize the submission for its first indication—BCG-unresponsive high-risk NMIBC—by mid-2026. Although cretostimogene grenadenorepvec has not yet received FDA approval, the Fast Track and Breakthrough Therapy statuses are expected to shorten review timelines. Some industry and payer reports project a possible U.S. launch in the fourth quarter of 2026, assuming timely authorization.

CG Oncology, Inc. (NASDAQ: CGON) is a late-stage biotech focused on NMIBC. Its lead pipeline asset is cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy. The company is conducting two pivotal Phase 3 studies: BOND-003 in over 400 high-risk, BCG-unresponsive patients and PIVOT-006 in an intermediate-risk cohort. While the BOND-003 results underpin the current BLA effort, CG Oncology has accelerated the primary analysis of PIVOT-006 to the first half of 2026, aiming to expand the drug’s indication into intermediate-risk NMIBC.

On the capital markets and governance front, CG Oncology increased its at-the-market (ATM) equity program limit to $550 million in January, bolstering its financing flexibility. On April 17, the stock reached an all-time high of $72.29, coinciding with the official appointment of Jim Dito as Chief Financial Officer. According to an SEC filing that same day, independent director James Mulry exercised 15,600 stock options at $36.63 per share under a pre-arranged 10b5-1 plan and sold them at $73.01. Two days earlier, President and COO Velete Ambro and Chief Medical Officer Vijay Kasturi received 107,508 and 79,216 stock option grants, respectively, at an exercise price of $67.68—part of a refreshed executive incentive structure ahead of the FDA approval milestone.